Table 1.

Demographic and clinical characteristics of the per-protocol study population (n=203).

Age; months Mean ± SD (range)	40±36 (3–144)
Gender (male: female;%)	57.6: 42.4
Stool frequency; number of watery stools in previous 24 hours Mean ±SD (range)	7.7±5.0 (3–30)
Vomiting frequency; number of episodes in previous 24 hours Mean ±SD (range)	3.2±3.6 (0–20)
Nausea (% patients)	59.1
Abdominal pain (% patients)	49.3
Dehydration (% patients)	25.6
Fever (% patients)	35.0
Antibacterial therapy (% patients)
Ceftriaxone	9.9
Cefuroxime	4.9
Ampicillin-sulbactam + amikacin, azithromycin, clarithromycin or metronidazole	4.0
Metronidazole	3.4
Ceftriaxone-metronidazole	3.0
Amoxicillin-clavulanic acid	2.5
Ampicillin-sulbactam	2.5
Cefdinir + amoxicillin-clavulanic acid or metronidazole	1.0
Cefixime	1.0
Cefuroxime-metronidazole	1.0
Cefdinir	0.5
Cefixime, ceftriaxone	0.5
Ceftazidime	0.5
Piperacillin, vancomycin, fluconazole	0.5
Other	1.0